Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting

  title={Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting},
  author={Chi-Un Pae},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  • C. Pae
  • Published 30 August 2006
  • Psychology, Medicine
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
Treatment of nausea with innovative antiemetics
This review will focus on innovative antiemetics in both aspects of basic pharmacology and evidence-based medicine by latest literatures in the palliative care field, including Kampo medicines, which are widely used in Japan for the relief of gastrointestinal symptoms related to advanced cancer.
Effect of Mirtazapine on Nausea in Children with Functional Nausea and Functional Dyspepsia Postprandial Distress Syndrome
Mirtazapine is an option for treating children and adolescents with functional nausea and nausea associated with functional dyspepsia post-prandial distress syndrome, especially for a select group of patients with concurrent weight loss, anxiety, and insomnia.
Optimizing Emetic Control in Children Receiving Antineoplastic Therapy
Existing guidelines for the prevention of antineoplastic chemotherapy-induced nausea and vomiting in children are constrained by the lack of robust evidence, and there is no information to guide the selection of alternative antiemetic agents for children who either cannot receive the recommended agents or who do not respond adequately to the treatment.
Mirtazapine for symptom control in refractory gastroparesis
It is concluded that mirtazapine improves nausea and vomiting, among other symptoms, in patients with gastroparesis and might be useful in select patients.
The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer
The latest literature that addresses some of the outstanding issues in the management of nausea and vomiting that is not directly related to treatment is presented.
[Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].
In patients with advanced cancer not being treated with chemotherapy or radiation therapy, metoclopramide can be used to reduce nausea and vomiting and the evidence level for prokinetics and neuroleptics is moderate to low.
Central Neuromodulators for Treating Functional GI Disorders: A Primer
Patients with functional GI disorders (FGIDs) are commonplace in the gastroenterologist's practice and there are benefits and potential adverse effects to using TCAs, SSRs, SNRIs, atypical antipsychotics, and miscellaneous central neuromodulators in these patients.
Newest Drugs for Chronic Unexplained Nausea and Vomiting
  • W. Hasler
  • Medicine
    Current Treatment Options in Gastroenterology
  • 2016
Current investigations will define potential therapeutic actions of agents that stimulate gastric emptying via action on gastroduodenal serotonin, motilin, and ghrelin receptors, which may broaden the treatment options for refractory cases of unexplained nausea and vomiting.
An Open-Label Long-Term Naturalistic Study of Mirtazapine Treatment for Depression in Cancer Patients
Relatively low doses of mirtazapine appeared to be safe and effective for treating cancer patients undergoing radiotherapy and/or chemotherapy, and the reduction in the severity of depressive symptoms was maintained until the end of the 24-week treatment period.


Mirtazapine for Treatment of Nausea Induced by Selective Serotonin Reuptake Inhibitors
A case of SSRI-induced nausea successfully treated with mirtazapine is reported, and the 5-HT antagonist cyproheptadine is associated with worsening of depressive symptoms when used to treat SSri-induced sexual dysfunction.
Mirtazapine (Remeron™) as Treatment for Non-Mechanical Vomiting after Gastric Bypass
It is concluded that mirtazapine may be a successful option to treat non-mechanical postoperative vomiting in morbidly obese patients after gastric bypass.
Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy
Nausea and vomiting disappeared within hours, pregnancy termination was no longer desired and the patient was discharged two weeks later in good health and at 36 weeks gestation a cesarean section was performed.
Mirtazapine: pharmacology in relation to adverse effects
  • D. Nutt
  • Psychology, Biology
    Acta psychiatrica Scandinavica. Supplementum
  • 1997
The unique pharmacology of mirtazapine means that it has a very different side effect profile from the tricyclic antidcpressants, producing less α1 adrenergic and musearinic blockade and causing much less nausea and sexual dysfunction.
Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine.
This report describes that addition of the new antidepressant mirtazapine may ameliorate nausea induced by serotonin reuptake-inhibiting antidepressants, presumably via 5-HT 3 receptor blockade.
The utility of antiemetics in the prevention and treatment of postoperative nausea and vomiting in patients scheduled for laparoscopic cholecystectomy.
  • Y. Fujii
  • Medicine
    Current pharmaceutical design
  • 2005
The efficacy of a combination of serotonin receptor antagonists (ondansetron and granisetron) and droperidol is superior to monotherapy with a serotonin receptor antagonist or droperodol, and adding dexamethasone to ondansetrons or granisettron improves antiemetic efficacy in PONV.
Population pharmacokinetic analysis of mirtazapine
The variability of mirtazapine plasma concentrations in clinical routine is caused to a relevant degree by CYP2D6, and should be taken into account when therapeutic drug monitoring is carried out to check treatment adherence or when a special clinical situation demands careful dosing of this drug.
Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms
Differences in metabolism between East Asians and Caucasians are common, especially in the activity of several phase I enzymes such as CYP2D6 and the CYP1C subfamily, and these differences are relevant for international drug approval when regulatory agencies must decide if they accept results from clinical trials performed in other parts of the world.